Swiss drugmaker Actelion forecasts earnings growth in 2016

By John Miller ZURICH (Reuters) - Actelion , Europe's largest biotechnology company, forecast that its core earnings would grow in 2016, defying concerns about rising generic competition in its main pulmonary arterial hypertension drug business. This year, Actelion expects a small percentage increase in core earnings at constant exchange rates. While that is under the 14 percent increase in 2015, it exceeds analyst forecasts for a potential drop in profit.